New hope for tough brain tumors: experimental drug targets recurrent meningioma
NCT ID NCT05023018
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests an experimental drug called NEO100 in people with a fast-growing type of brain tumor called high-grade meningioma that remains after surgery, has progressed, or returned. About 30 participants will take NEO100 four times daily in 28-day cycles. The main goal is to see if the drug can stop the tumor from growing for at least six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor Scott and White
RECRUITINGDallas, Texas, 75246, United States
Contact
-
Saint John Cancer Institute
RECRUITINGSanta Monica, California, 90404, United States
Contact
-
Sutter Health Research Institute
RECRUITINGSan Francisco, California, 94110, United States
Contact
-
Tufts Medical Center
RECRUITINGBoston, Massachusetts, 02111, United States
Contact
-
University of Southern California
RECRUITINGLos Angeles, California, 90033, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.